Scientific
MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis
These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.
Affected Genes

Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
description Ratio Regulation Class Gene Ontology Gene Accession Minimum Ratio Maximum Ratio
Results: HTML CSV LaTeX
Showing element 1 to 50 of 91 in total
Class: cellular component
Gene Ontology: nucleus

\def\wcA{0.25\textwidth}
\def\wcB{0.25\textwidth}
\def\wcC{0.25\textwidth}
\begin{longtable}{|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
Ratio\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Regulation\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Antigen KI-67. \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.73211\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
down\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
AT-hook-containing transcription factor 1 (Embryonic large molecule derived from yolk sac). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
3.83977\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Ataxin-7 (Spinocerebellar ataxia type 7 protein). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2.29381\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
up\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Calcium/calmodulin-dependent protein kinase type 1B (EC 2.7.11.17) (CaM kinase IB) (CaM kinase I beta) (CaMKI-beta) (CaM-KI beta) (Pregnancy up-regulated non-ubiquitously expressed CaM kinase). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.61673\vspace{3pt}}&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Calpain-3 (EC 3.4.22.54) (Calpain L3) (Calpain p94) (Calcium-activated neutral proteinase 3) (CANP 3) (Muscle-specific calcium-activated neutral protease 3) (nCL-1). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2.87038\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Calsenilin (Kv channel-interacting protein 3) (KChIP3) (A-type potassium channel modulatory protein 3) (DRE-antagonist modulator) (DREAM). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
3.27919\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
down\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
CCR4-NOT transcription complex subunit 2 (CCR4-associated factor 2). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.30082\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Centromere protein L (CENP-L) (Interphase centromere complex protein 33). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.78708\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
up\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Centromere protein S (CENP-S) (Apoptosis-inducing TAF9-like domain- containing protein 1). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2.7017\vspace{3pt}}&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Chromodomain helicase-DNA-binding protein 4 (EC 3.6.1.-) (ATP- dependent helicase CHD4) (CHD-4) (Mi-2 autoantigen 218 kDa protein) (Mi2-beta). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.78439\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Chromodomain-helicase-DNA-binding protein 6 (EC 3.6.1.-) (ATP- dependent helicase CHD6) (CHD-6) (Radiation-induced gene B protein). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.60746\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
down\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Chromodomain-helicase-DNA-binding protein 7 (EC 3.6.1.-) (ATP- dependent helicase CHD7) (CHD-7). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.25808\vspace{3pt}}&\multirow{4}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
up\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Cisplatin resistance-associated overexpressed protein (cAMP regulatory element-associated protein 1) (CRE-associated protein 1) (CREAP-1) (Luc7A) (Okadaic acid-inducible phosphoprotein OA48-18). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2.91954\vspace{3pt}}&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Cyclin-A2 (Cyclin-A). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.45635\vspace{3pt}}&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Cysteine desulfurase, mitochondrial precursor (EC 2.8.1.7). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.19539\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Disco-interacting protein 2 homolog C. \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.21384\vspace{3pt}}&\multirow{5}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
down\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
DNA-directed RNA polymerase III subunit RPC8 (RNA polymerase III subunit C8) (DNA-directed RNA polymerase III subunit H) (DNA-directed RNA polymerase III subunit 22.9 kDa polypeptide). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
6.56408\vspace{3pt}}&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
E3 ubiquitin-protein ligase CHFR (EC 6.3.2.-) (Checkpoint with forkhead and RING finger domains protein) (RING finger protein 196). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.30869\vspace{3pt}}&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Enhancer of polycomb homolog 1. \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
4.49282\vspace{3pt}}&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Exosome complex exonuclease RRP44 (EC 3.1.13.-) (Ribosomal RNA- processing protein 44) (DIS3 protein homolog). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.683\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Forkhead box protein P2 (CAG repeat protein 44) (Trinucleotide repeat- containing gene 10 protein). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.57088\vspace{3pt}}&\multirow{4}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
up\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
GC-rich sequence DNA-binding factor (GCF) (Transcription factor 9) (TCF-9). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.69345\vspace{3pt}}&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Geminin. \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.35125\vspace{3pt}}&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Golgin subfamily B member 1 (Giantin) (Macrogolgin) (372 kDa Golgi complex-associated protein) (GCP372). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.45148\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Hematological and neurological expressed 1 protein (Androgen-regulated protein 2). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
3.62109\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
down\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Homeobox protein Hox-D3 (Hox-4A). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.27461\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Homeobox protein Nkx-2.8 (Homeobox protein NK-2 homolog H). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.30407\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
up\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Homeobox protein SIX4 (Sine oculis homeobox homolog 4). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
3.70292\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Homeobox protein TGIF2 (5'-TG-3'-interacting factor 2) (TGFB-induced factor 2) (TGF(beta)-induced transcription factor 2). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
3.48313\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
down\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
HORMA domain-containing protein 1 (Newborn ovary HORMA protein) (Cancer/testis antigen CT46). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.22047\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
up\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
LAG1 longevity assurance homolog 4. \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.50206\vspace{3pt}}&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Lariat debranching enzyme (EC 3.1.-.-). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.37411\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Melanoma-associated antigen C2 (MAGE-C2 antigen) (MAGE-E1 antigen) (Hepatocellular carcinoma-associated antigen 587) (Cancer-testis antigen 10) (CT10). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.29952\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
down\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Methyl-CpG-binding domain protein 1 (Methyl-CpG-binding protein MBD1) (Protein containing methyl-CpG-binding domain 1). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.22576\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
up\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Myelin transcription factor 1-like protein (MyT1L protein) (MyT1-L). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2.58329\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
down\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
N-glycosylase/DNA lyase [Includes: 8-oxoguanine DNA glycosylase (EC 3.2.2.-); DNA-(apurinic or apyrimidinic site) lyase (EC 4.2.99.18) (AP lyase)]. \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.35022\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
up\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Nuclear factor of activated T-cells, cytoplasmic 3 (NF-ATc3) (NFATc3) (T cell transcription factor NFAT4) (NF-AT4) (NFATx). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
5.32612\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
down\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Nuclear pore complex protein Nup153 (Nucleoporin Nup153) (153 kDa nucleoporin). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.48389\vspace{3pt}}&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Nuclear receptor ROR-alpha (Retinoid-related orphan receptor-alpha) (Nuclear receptor RZR-alpha). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.98137\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Nuclear receptor-binding factor 2 (NRBF-2) (Comodulator of PPAR and RXR). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.10889\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
up\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Nuclear RNA export factor 2 (TAP-like protein 2) (TAPL-2). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.19207\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Nucleolar preribosomal-associated protein 1 (Fragment). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.36755\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
down\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Nucleoplasmin-2. \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
5.83544\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Opa-interacting protein 5. \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2.72371\vspace{3pt}}&\multirow{4}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
up\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Parathyroid hormone/parathyroid hormone-related peptide receptor precursor (PTH/PTHr receptor) (PTH/PTHrP type I receptor). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
4.55371\vspace{3pt}}&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
PDZ and LIM domain protein 2 (PDZ-LIM protein mystique) (PDZ-LIM protein). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
5.81102\vspace{3pt}}&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
POU domain class 2-associating factor 1 (B-cell-specific coactivator OBF-1) (OCT-binding factor 1) (BOB-1) (OCA-B). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.44789\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Pre-mRNA-splicing factor SYF2 (CCNDBP1-interactor) (p29). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
3.43019\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
down\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Prostaglandin G/H synthase 2 precursor (EC 1.14.99.1) (Cyclooxygenase- 2) (COX-2) (Prostaglandin-endoperoxide synthase 2) (Prostaglandin H2 synthase 2) (PGH synthase 2) (PGHS-2) (PHS II). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.18096\vspace{3pt}}&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Protein CWC15 homolog. \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.25205\vspace{3pt}}&\\\hline
nd{longtable}

Legend:
- The Ratio specifies how much this gene is up/down regulated. When up- or down-regulated must this value respectively be multiplied/divided to obtain the MK5 on concentration based on the MK5 off concentration.

 - The Regulation specifies how this gene is affected when going from the MK5 off cells to the MK5 on cells. 

 - The Class refers to the ontology category, which can be molecular_function, biological_process or cellular_component. 

 - The Gene Ontology terms as linked to the specific gene.

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Accession is the GO accession key. 

 - Minimum Ratio is the lowest expected regulation ratio based on the replicate slides and a 95% symmetric confidence interval.

 - Maximum Ratio is the highest expected regulation ratio based on the replicate slides and a 95% symmetric confidence interval.
- http://analysis.yellowcouch.org/